Jessica Pack
Family · Lynchburg, VANPI 1629609359
Payments from drug & device makers
Across 44 payments — averaging $79.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$451
- AbbVie$398
- Novo Nordisk$397
- Dexcom, Inc.$331
- Amgen$219
- Sanofi-aventis U.S. LLC$197
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,511100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $451 |
| AbbVie | 5 | $398 |
| Novo Nordisk | 6 | $397 |
| Dexcom, Inc. | 3 | $331 |
| Amgen | 3 | $219 |
| Sanofi-aventis U.S. LLC | 2 | $197 |
| GSK | 2 | $167 |
| Medtronic | 2 | $163 |
| SK Life Science, Inc. | 2 | $138 |
| Lundbeck LLC | 1 | $121 |
| Phathom Pharmaceuticals, Inc. | 1 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $111 |
| Merck | 1 | $110 |
| Argenx US, Inc. | 1 | $88 |
| Vertex | 1 | $87 |
| Otsuka America Pharmaceutical, Inc. | 1 | $86 |
| Biogen | 1 | $71 |
| BETA Bionics, Inc. | 1 | $70 |
| Grifols USA, LLC | 1 | $58 |
| Pfizer | 1 | $53 |
| Johnson & Johnson | 1 | $38 |
| CSL Behring | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,511 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humalog Kwikpen U-100Insulin Lispro | 23 | $4,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $3,607 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $2,443 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 39 | $2,227 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 12 | $672 |
| Glipizide | 16 | $36 |
Paid to pharmacies, not to this prescriber.
Other family in Lynchburg
- Amy StowersLynchburg$23K
- Elizabeth CopesLynchburg$23K
- Shauntell KlineLynchburg$15K
- Haley RussellLynchburg$13K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.